In this cohort, the median OS and PFS of DLBCL patients with HBV infection was shorter than those with HBV-free, and then we further explored potential adverse prognostic factors of DLBCL patients, such as sex, age, clinical stage, IPI, Ki-67, molecular subtype, chemotherapy regimens, MYC and BCL2 rearrangements, and HBV status; and multivariable analysis showed that IPI, chemotherapy regimens, and MYC gene rearrangements were independent risk factors for DLBCL patients. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.